AzTrials
AzTrials

Systemic SclerosisPhase 2DISTOL-1NCT00775463

Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine

A Phase 2 study testing treprostinil diethanolamine in people with Systemic Sclerosis and Scleroderma, run by United Therapeutics at 30 sites in 3 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study will evaluate the effect of treprostinil diethanolamine (UT-15C) sustained release tablets(compared to placebo) on digital ulcers in patients with scleroderma. Treprostinil diethanolamine is an analog of prostacyclin. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Systemic Sclerosis, Scleroderma
What is being tested?
treprostinil diethanolamine
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
148 participants
Where
30 sitesin 3 countries
Study dates
May 2009to Jul 2011
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Subject gave voluntary written informed consent to participate in the study
  • Diagnosis of systemic sclerosis (SSc) as defined by American College of Rheumatology (ACR) criteria
  • Males and females age greater than 18 years at Screening
  • Presence of at least one active digital ulcer (met protocol defined qualifications for active digital ulcer) at Baseline
  • Females of childbearing potential willing to use a reliable form of medically acceptable contraception and have a negative pregnancy test at Screening and Baseline
  • Able to communicate effectively with study personnel and willing to comply with protocol requirements

Who cannot join

  • Diagnosis of pulmonary arterial hypertension (PAH)
  • Body weight less than 40 kg at Screening and confirmed at Baseline
  • History of postural hypotension, unexplained syncope, a blood pressure that is less than 90 mmHg systolic or 50 mmHg diastolic at Screening and Baseline
  • Hemoglobin concentration less than 75% of the lower limit of the normal range at Screening
  • Moderate to severe hepatic impairment, i.e., Child-Pugh Class B or C, or ALT greater than three times upper limit of normal
  • Intractable diarrhea, or severe malabsorption, defined as greater than 15% unintentional loss of body weight in the last 6 months prior to Screening; any severe organ failure (e.g., lung, kidney), bleeding diathesis or platelet disorder, or any life-threatening condition
Show all 19Show fewer
  • Pregnant or breast-feeding
  • Simultaneously fulfilled criteria for a second connective tissue disease including systemic lupus erythermatosus, rheumatoid arthritis or inflammatory myopathy
  • Sympathectomy of the upper limb, involving the hand, performed within 12 months of Baseline. Sympathectomy performed on the non-target limb (hand not presenting with qualifying ulcers) or which did not include the hand, performed within 6 months of Baseline
  • Receipt of prostanoid treatment (epoprostenol, treprostinil sodium, or other prostacyclin analog) within the previous 3 months of Baseline for conditions including Raynaud's phenomenon, rest pain and / or digital ulcers
  • Required systemic antibiotics for infected digital ulcers within 2 weeks of Screening
  • Local injection of botulinum toxin in an affected finger within 1 month prior to Baseline
  • Treatment with endothelin receptor antagonists within 1 month prior to Baseline
  • Patients on phosphodiasterase inhibitors, such as sildenafil or tadalafil, who have received treatment for less than 6 months prior to Baseline (unless for intermittent treatment of male erectile dysfunction)
  • Treatment with statin within 1 month prior to Screening, unless for management of hyperlipidemia
  • Received an investigational product within 1 month preceding Screening
  • Known hypersensitivity to treprostinil diethanolamine or any of the excipients
  • Tobacco or nicotine use at any level within the past 6 months prior to Screening
  • Any condition or laboratory that in the opinion of the investigator might interfere with subject's participation, pose an additional risk for the subject, could prevent understanding the objectives, nature or consequences of the trial, compliance with the protocol, adherence to therapy, or that would interfere with interpretation of study assessments

Trial locations and contacts

30 sites in 3 countries.

30 sites in 3 countries

United States24 sites
  • University of Michigan Scleroderma Program

    Ann Arbor, Michigan, 48106

  • Denver Medical Center

    Aurora, Colorado, 80045

  • Johns Hopkins University - Division of Rheumatology

    Baltimore, Maryland, 21224

  • University of Alabama - Arthritis Clinical Intervention Program

    Birmingham, Alabama, 35294

  • Boston University School of Medicine

    Boston, Massachusetts, 02118

  • Medical University of South Carolina

    Charleston, South Carolina, 29425

  • Northwestern University - Feinberg School of Medicine

    Chicago, Illinois, 60611

  • Cleveland Clinic Foundation

    Cleveland, Ohio, 44195

  • University of Connecticut Health Center

    Farmington, Connecticut, 06030

  • University of Texas - Houston

    Houston, Texas, 77030

  • University of Indiana School of Medicine

    Indianapolis, Indiana, 46202

  • North Shore-LIJ Health System

    Lake Success, New York, 11042

  • UCLA

    Los Angeles, California, 90095

  • Medical College of Wisconsin

    Milwaukee, Wisconsin, 53226

  • University of Minnesota

    Minneapolis, Minnesota, 55455

  • UMDNJ Clinical Research Center

    New Brunswick, New Jersey, 08903

  • The Hospital for Special Surgery

    New York, New York, 10021

  • Stanford University School of Medicine/Palo Alto VA Health Care System

    Palo Alto, California, 94304

  • University of Pittsburgh

    Pittsburgh, Pennsylvania, 15261

  • University of Utah

    Salt Lake City, Utah, 84132

  • Mayo Clinic Scottsdale

    Scottsdale, Arizona, 85259

  • Virginia Mason Medical Center

    Seattle, Washington, 98111

  • University of Toledo

    Toledo, Ohio, 43614

  • Georgetown University

    Washington D.C., District of Columbia, 20007

Other trials in United States

Canada3 sites
  • Dalhousie University - QEII Health Science Center

    Halifax, Nova Scotia, B3H4K4

  • St Joseph's Health Care

    London, Ontario, N6A4V2

  • McGill University

    Montreal, Quebec, H3T1E2

Other trials in Canada

United Kingdom3 sites
  • Clinical Sciences Center - University Hospital

    Liverpool, L9 7AL

  • Royal Free Hospital - Center for Rheumatology

    London, NW32QG

  • Salford Royal Hospital

    Manchester, M139PT

Other trials in United Kingdom

About this study

Official title: DISTOL-1: Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine: A Randomized, Double-blind, Placebo-controlled, Multicenter Study

This study will evaluate the effect of treprostinil diethanolamine (UT-15C) sustained release tablets(compared to placebo) on digital ulcers in patients with scleroderma. Treprostinil diethanolamine is an analog of prostacyclin. Prostacyclin is a naturally occuring substance produced by the cells of blood vessels that inhibits platelet aggregation, induces vasodilation, and suppresses smooth muscle proliferation. Improvement in blood flow in lower limbs and fingers would be anticipated to result in a reduction in ischemic pain, Raynaud's phenomenon and promote healing of digital ulcers and other ischemic wounds.

Being tested
treprostinil diethanolamine, placebo
Keywords
Scleroderma, Diffuse, Scleroderma, Limited, Scleroderma, Systemic, Ulcer, prostacyclin
Medical subject headings
Scleroderma, Systemic, Scleroderma, Diffuse, Scleroderma, Limited, Ulcer

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • treprostinil diethanolamineDrug

    oral sustained release tablet. Maximum tolerable dose not exceeding 16 mg twice daily (BID)

  • placeboDrug

Study groups in NCT00775463
Study groupRoleWhat they receive
treprostinil diethanolamineExperimentalTreprostinil diethanolamine sustained release tablet initiated at 0.25 mg BID and titrated up to a maximum dose of 16 mg BID or the individual's maximum tolerated dose.
Receives: Drug: treprostinil diethanolamine
placebo (sugar pill)Placebo comparatorMatching placebo sustained release tablet initiated at 0.25 mg BID and titrated up to a maximum dose of 16 mg BID or the individual's maximum tolerated dose.
Receives: Drug: placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Net Ulcer Burden

    Net ulcer burden was defined as the number of "new" or "active" digital ulcers (DU), plus the number of "indeterminate" DUs at that assessment that have previously been classified as either "active" or "new" at any earlier assessment during the study. A DU was defined as an area with visually discernable depth and a loss of continuity of epithelial coverage, which could be denuded or covered by a scab or necrotic tissue. If denuded, the DU was pronounced "active." If denudation could not be judged because of the presence of scab or necrotic tissue, DU presenting with features, including underlying pain, based on Investigator clinical judgment to be consistent with loss of epithelialization, epidermis, or dermis, and requiring treatment were designated as "active." Otherwise, the DU was pronounced "indeterminate." Only DUs distal to the proximal interphalangeal joints, volar to the equator of the finger, not localized in creases and vascular in origin were assessed.

    Measured: Week 20

Secondary outcomes (11)
  1. Digital Ulcer Pain VAS

    Digital ulcer pain was rated on a 100-mm VAS on which subjects were asked to rate their average overall hand pain during the last week. The recorded value was divided by 10, with values ranging from 0.0 (no pain) to 10.0 (unbearable pain), expressed to one decimal.

    Measured: Week 20

  2. Patient Global Assessment of Digital Ulcer Severity VAS

    Patients rated their global impression of digital ulcer severity on a 15-cm VAS from scaled 0 (no disease activity) to 100 (very severe disease).

    The term "severity" was used to measure the extent of disease activity and associated disability or discomfort the patient experienced during the indicated time period.

    Measured: Week 20

  3. Physician Global Assessment of Digital Ulcer Severity VAS

    Physicians rated their global impression of digital ulcer severity on a 15-cm VAS from scaled 0 (no disease activity) to 100 (very severe disease).

    The term "severity" was used to measure the extent of disease activity and associated disability or discomfort the patient experienced during the indicated time period.

    Measured: Week 20

  4. Cochin Hand Function Scale (CHFS)

    The CHFS has been demonstrated as a reliable and valid assessment of hand function at the activity level in persons with SSc. It is comprised of 18 questions with possible integer responses of 0 (without difficulty) to 5 (impossible). The CHFS Score is simply the sum of all 18 questions, divided by the number of questions actually answered, multiplied by 18. At least 10 of the 18 questions must have been answered in order for CHFS to be calculated. Therefore, CHFS Score values can range from 0 (least limitation) to 90 (most limitation). A higher score indicates more difficulty in hand function or greater disability.

    Measured: Week 20

  5. Scleroderma Health Assessment Questionnaire (SHAQ)

    The SHAQ is a patient self-administered instrument which has been previously validated in SSc and demonstrates meaningful clinical changes in the course of the disease over time. It is comprised of a 20 question instrument pertaining to specific activities with possible integer responses of 0 (without any difficulty) to 3 (unable to do), and five additional scleroderma-specific visual analog scale (VAS) domains (Overall Disease Activity, Raynaud's Phenomenon, Finger Ulcers, Breathing, and Intestinal Problems) with possible values ranging from 0.0 to 15.0. The 20 questions are divided into eight domains. A mean score is calculated for each domain ranging from 0 to 3. A composite HAQ DI score is calculated by dividing the summed domain scores by the number of domains answered. The composite score is reported, falling between 0 and 3 on an ordinal scale. The scores are interpreted as 0 (no impairment in function) to 3 (maximal impairment of function).

    Measured: Week 20

  6. Modified Rodnan Skin Score (mRSS)

    The skin thickening was assessed by the Investigator in 17 body areas: fingers, hands, forearms, arms, feet, legs, and thighs (bilaterally) and face, chest, and abdomen (singly). Each area was scored 0-3; 0 representing normal skin and 3 being severe thickening. The mRSS was the sum of the individual skin assessment scores: possible range of 0-51; 0 (no thickening) to 51 (severe thickening in all 17 areas) .

    Measured: Week 20

  7. Short-Form McGill Pain Questionnaire

    The SF-MPQ assessment has three component scores: the pain rating index (PRI), a pain visual analogue numerical scale (Pain VAS) and the present pain intensity (PPI). PRI is calculated by summing the responses (0=None to 3=Severe) to the 15 questions describing pain during the previous week and rated on an intensity scale as 0= none, 1= mild, 2= moderate or 3= severe and has possible values ranging from 0 to 45. The Pain VAS is a 100 mm VAS on which subjects were asked to rate pain during the previous week with values ranging from no pain (0.0) to worst possible pain (10.0). The PPI rated pain on a 6-point category scale from 0 (no pain) to 5 (excruciating pain).

    Measured: Week 20

  8. Patient Impression of Change (PIC) Questionnaire

    The PIC questionnaire consisted of three Likert items that asked the subject to rate changes in their digital ulcer, Raynaud's phenomenon and disease status since their last visit on a seven-level scale (very much improved, much improved, somewhat improved, same, somewhat worse, much worse and very much worse).

    Measured: Week 20

  9. Short Form 36

    Change in patient quality of life was measured by the Medical Outcomes Study 36-Item Short Form Health Survey (SF-36), a self-administered questionnaire covering eight areas: physical function, physical role, bodily pain, general health, vitality, social function, emotional role, and mental health. For each area, the score range from 0 (poorer health status) to 100 (better health status). The SF-36 is one of the most widely used and validated instruments to assess quality of life in patients with systemic illnesses. A decrease (negative change) in a domain score corresponds to deterioration.

    Measured: Week 20

  10. Time to Ulcer Healing- Percentage of Subjects With Complete Healing

    A subject was counted as having all ulcers completely healed at the earliest assessment for which all ulcers are designated as "healed" and no new ulcers appeared for the remainder of the trial.

    Measured: Week 20

  11. Time to Ulcer Healing

    A subject was counted as having all ulcers completely healed at the earliest assessment for which all ulcers are designated as "healed" and no new ulcers appeared for the remainder of the trial. The time to complete healing of all ulcers were calculated as the number of days from randomization to the date of these respective assessments, provided that complete healing was achieved during the study.

    Measured: Week 20

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Oct 2008 (estimated)
  2. Study startMay 2009
  3. Primary completionMar 2011
  4. Study completionJul 2011

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
148 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00775463
Sponsor's protocol ID
TDE-DU-201
Acronym
DISTOL-1
Status last verified
Dec 2023
First submitted
17 Oct 2008
Last updated
28 Dec 2023
Data monitoring committee
No

Publications

  • Mecoli CA, Perin J, Van Eyk JE, Zhu J, Fu Q, Allmon AG, Rao Y, Zeger S, Wigley FM, Hummers LK, Shah AA. Vascular biomarkers and digital ulcerations in systemic sclerosis: results from a randomized controlled trial of oral treprostinil (DISTOL-1). Clin Rheumatol. 2020 Apr;39(4):1199-1205. doi: 10.1007/s10067-019-04863-0. Epub 2019 Dec 19.

    PubMed 31858338

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing treprostinil diethanolamine in people with Systemic Sclerosis and Scleroderma, run by United Therapeutics at 30 sites in 3 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 28 Dec 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 30 sites in United States, Canada, United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 17 Mar 2014). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Net Ulcer Burden (time frame: Week 20). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00775463, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Dec 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in